利拉利汀是由Boehringer Ingelheim開發(fā)的用于治療2型糖尿病的二肽基肽酶-4抑制劑。
-
默認(rèn)
常備現(xiàn)貨
-
純度
- 請選擇
- 99+%
- 99%
- 98+%
- 98%
- 97+%
- 97%
- 96+%
- 96%
- 95+%
- 95%
- 93%
- 90+%
- 90%
規(guī)格
- 請選擇
- 1mg
- 2mg
- 5mg
- 10mg
- 25mg
- 50mg
- 100mg
- 250mg
- 1g
- 5g
- 10g
- 25g
- 100g
- 500g
- 1000g
- 1kg
清空選項
-
(2S,3S)-2,3-Dihydroxysuccinic acid
-
BD123219147-71-798%
-
¥62.00100g常備現(xiàn)貨
-
Piperidin-3-amine
-
BD249954012-73-695%
-
¥145.00250mg常備現(xiàn)貨
-
(R)-Piperidin-3-amine dihydrochloride
-
BD2500334618-23-497%
-
¥132.0025g常備現(xiàn)貨
-
(R)-tert-Butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
-
BD632930668273-75-497% HPLC
-
¥237.001g常備現(xiàn)貨
-
1-Bromo-2-butyne
-
BD573033355-28-097%
-
¥28.001g常備現(xiàn)貨
-
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
-
BD232385666816-98-498%
-
¥32.001g常備現(xiàn)貨
-
(R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
-
BD161416668270-12-098%
-
¥83.00250mg常備現(xiàn)貨
-
(R)-tert-Butyl piperidin-3-ylcarbamate
-
BD0330309956-78-397%
-
¥137.0025g常備現(xiàn)貨
-
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
-
BD233973853029-57-999%
-
¥52.001g常備現(xiàn)貨
-
2-(Chloromethyl)-4-methylquinazoline
-
BD168632109113-72-698%
-
¥32.001g常備現(xiàn)貨
-
8-Bromo-3-methyl-1H-purine-2,6(3H,7H)-dione
-
BD16866693703-24-398%
-
¥151.0025g常備現(xiàn)貨
-
(R)-2-(Piperidin-3-yl)isoindoline-1,3-dione (2S,3S)-2,3-dihydroxysuccinate
-
BD247483886588-62-195+%
-
¥97.001g常備現(xiàn)貨
-
(R)-EThylpiperidine-3-carboxylate(2R,3R)-2,3-dihydroxysuccinate
-
BD75649983602-37-397%
-
¥440.005g
-
(R)-7-(But-2-ynyl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
-
BD00799120886588-63-298%
-
¥681.001g